Details
- US Trade Representative Jamieson Greer announced the investigation on June 18, saying it would examine Germany’s pricing policies for innovative medicines.
- The probe was opened under Section 301 of the Trade Act, which allows Washington to take action against foreign practices it considers unfair or harmful to US commerce.
- US officials say Germany’s system of negotiated prices, mandatory rebates and discounts keeps medicine prices artificially low compared with the United States.
- Washington argues that American patients are left carrying a disproportionate share of global pharmaceutical research and development costs.
- Germany unveiled healthcare reforms in April aimed at reducing a projected €20 billion funding gap in its statutory health-insurance system.
- Initial proposals included variable discounts on medicines, though Berlin has since revised parts of the plan after objections from the pharmaceutical industry.
- The investigation will include written submissions from June 25 and a public hearing scheduled for September.
- If Washington finds Germany’s policies unfair, it could impose tariffs or other trade restrictions on German imports.
- German Chancellor Friedrich Merz said pharmaceutical reimbursement is a matter of national jurisdiction and that Berlin is prepared to provide information to US officials.
- Merz also said he expects the United States to respect its trade agreement with the European Union.
What Else
The dispute adds another source of tension to US-European trade relations as Washington pushes allies to pay more for innovative medicines. The outcome could increase pressure on European governments balancing lower medicine costs, public health budgets and access to new drugs.
